Filana Therapeutics (FLNA) CEO Barry Richard Buys Stock

What Happened
Barry Richard, President & CEO and a director of Filana Therapeutics (FLNA), made two open-market purchases of company stock: 206,813 shares on 2026-09-29 at a weighted average price of $0.90 (total $186,132) and 100,000 shares on 2026-09-30 at a weighted average price of $0.92 (total $92,000). Combined, he acquired 306,813 shares for $278,132. These were purchases (insider buying), which investors often view as a sign of confidence, though no motivation is stated.

Key Details

• Transaction dates & prices:
  • 2026-09-29 — Purchase of 206,813 shares at a weighted average $0.90 (total $186,132). (See footnote F1.)
  • 2026-09-30 — Purchase of 100,000 shares at a weighted average $0.92 (total $92,000). (See footnote F2.)
• Method: Open-market purchases (transaction code P).
• Shares owned after transaction: Not disclosed in the provided Form 4.
• Footnotes: F1 and F2 state the reported prices are weighted averages from multiple open-market trades. F1 price range: $0.86–$0.94; F2 price range: $0.91–$0.93. The reporter offers to provide detailed breakdowns on request.
• Filing timeliness: Form 4 was filed 2026-10-01 for transactions on 2026-09-29 and 2026-09-30; no late filing flag is indicated in the provided information.

Context
This report documents straightforward open-market purchases by an executive (not option exercises, gifts, or tax withholding). Insider purchases can attract attention from retail investors as one data point about management’s view of company value, but they do not, by themselves, explain the insider’s motives.